Parabilis Medicines financials
$27.25−3.78%
Close Nov 2, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 |
|---|---|
| Revenue | $148.0K |
| Gross profit | $148.0K |
| Gross margin | 100.0% |
| Operating income | -$50.9M |
| Net income | -$67.0M |
| Net margin | −45239.9% |
| Diluted EPS | $-2.32 |
| EBITDA | -$50.9M |
| Operating cash flow | — |
| Free cash flow | — |
| Diluted shares | 28.9M |
Balance sheet
| Period end | Jun 30 |
|---|---|
| Cash & equivalents | $1.09B |
| Short-term investments | $33.6M |
| Total debt | $7.5M |
| Total assets | $1.18B |
| Total liabilities | $127.5M |
| Shareholders' equity | $1.05B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology